Terms: = Cervical cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Clinical Outcome
3 results:
1. bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma.
Pillai MR; Jayaprakash PG; Nair MK
J Cancer Res Clin Oncol; 1999; 125(1):55-60. PubMed ID: 10037278
[TBL] [Abstract] [Full Text] [Related]
2. p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions.
Kurvinen K; Syrjänen K; Syrjänen S
J Clin Oncol; 1996 Jul; 14(7):2120-30. PubMed ID: 8683245
[TBL] [Abstract] [Full Text] [Related]
3. p53 mutation and mdm2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract] [Full Text] [Related]
